Volume 3.46 | Nov 24

Mammary Cell News 3.46, November 24, 2011
Mammary Cell News
     In this issue: Publications | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter
Researchers Find Genetic Rearrangements Driving 5 to 7 Percent of Breast Cancers
Researchers have discovered two cancer-spurring gene rearrangements that may trigger 5% to 7% of all breast cancers. [Press release from the University of Michigan Comprehensive Cancer Center discussing online prepublication in Nature Medicine] Press Release | Abstract

Listen Now: New Podcast on ALDH in Breast Cancer Treatment Response
PUBLICATIONS (Ranked by Impact Factor of the Journal)

PBX1 Genomic Pioneer Function Drives ERα Signaling Underlying Progression in Breast Cancer
Researchers demonstrate that PBX1 acts as a pioneer factor and is essential for the estrogen receptor α (ERα)-mediated transcriptional response driving aggressive tumors in breast cancer. [PLoS Genet]
Abstract | Press Release

Gene Expression Profiling Identifies Soluble Form of ST2 as an Effector of ErbB2-Driven Breast Carcinoma Cell Motility, Associated with Metastasis
To identify genes that mediate ErbB2-driven cell motility, scientists performed differential gene expression analysis of ErbB2-expressing migrating breast cancer cells vs. mutant ErbB2-expressing non-migrating cells. [Oncogene] Abstract

p21-Activated Kinase 1 Is a Breast Cancer Oncogene that Coordinately Activates MAPK and MET Signaling
To identify breast cancer oncogenes that activate the MAPK pathway, investigators screened a library of human kinases for their ability to induce anchorage-independent growth in a derivative of immortalized human mammary epithelial cells. [Oncogene] Abstract

WEE1 Inhibition Sensitizes Basal Breast Cancer Cells to TRAIL-Induced Apoptosis
In this study, scientists tested the effects of WEE1 inhibition on Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL)-mediated apoptosis in breast cancer cell lines. [Mol Cancer Res] Abstract

Targeting Abnormal DNA Repair in Therapy-Resistant Breast Cancers
Here researchers show that tamoxifen- and aromatase-resistant derivatives of MCF7 cells and estrogen receptor- and progesterone receptor-negative cells have even higher steady state levels of DNA ligase IIIα and increased levels of poly (ADP-ribose) polymerase, another alternative non-homologous end-joining component. [Mol Cancer Res] Abstract

Cross-Talk Between Endothelial and Breast Cancer Cells Regulates Reciprocal Expression of Angiogenic Factors In Vitro
Using an in vitro co-culture system, scientists investigated the influence of endothelial cells on the angiogenic phenotype of breast cancer cells. [J Cell Biochem] Abstract


A Case-Match Study Comparing Unilateral with Synchronous Bilateral Breast Cancer Outcomes
The purpose of this study was to determine whether survival outcomes for patients with synchronous bilateral breast cancer can be estimated from the characteristics of their individual cancers. [J Clin Oncol] Abstract

Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial
Women with axillary node–positive or high-risk node-negative breast cancer were randomly assigned to receive either three cycles of docetaxel and capecitabine followed by three cycles of cyclophosphamide, epirubicin, and capecitabine (n = 753) or three cycles of docetaxel followed by three cycles of cyclophosphamide, epirubicin, and fluorouracil (n = 747). [J Clin Oncol] Abstract

Free Nature Immunology Webcast: HIV Vaccines.
Generex Subsidiary Antigen Express to Present AE37 Cancer Vaccine Phase II Clinical Data
Generex Biotechnology Corporation announced that its wholly-owned subsidiary, Antigen Express, Inc., will present new Phase II clinical data from its study of a novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37) in HER-2 expressing breast cancer patients. [Press release from Generex Biotechnology Corporation discussing research to be presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio] Press Release

Peregrine Reports Promising 23.2 Month Median Overall Survival from Phase II Advanced Breast Cancer Trial
Peregrine Pharmaceuticals, Inc. announced 23.2 month median overall survival from a single-arm phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in patients with locally advanced or metastatic breast cancer. [Peregrine Pharmaceuticals, Inc.] Press Release
Genentech Plans New Avastin Trial
In the wake of the US Food and Drug Administration’s decision to revoke approval of Avastin for the treatment of metastatic breast cancer, drug maker Genentech says it will conduct a new clinical trial to determine which patients are likely to benefit from the drug. [The Scientist] Press Release

First Patients Enrolled in Project to Improve NHS Cancer Gene Testing
Cancer Research UK has started recruiting patients for a pioneering initiative to demonstrate how genetic tests could be used within the National Health Service (NHS) to help match cancer patients to the most appropriate treatment, while building a database of information for research into new targeted therapies. [Cancer Research UK] Press Release

Canadian Breast Cancer Foundation Awards a Record $10 Million to Support Breast Cancer Research and Community Projects
The Canadian Breast Cancer Foundation – Prairies/NWT Region announced the funding of 36 research and community projects. Totaling $10 million, these funds support initiatives in Alberta, Saskatchewan, Manitoba and the Northwest Territories (NWT). [Canadian Newswire] Press Release
The Canadian Task Force on Preventive Health Care Releases Updated Guideline for Breast Cancer Screening in Average Risk Women
The Canadian Task Force on Preventive Health Care released an updated guideline for breast cancer screening in average risk women aged 40 – 74. [Canadian Task Force on Preventive Health Care, Canada] Press Release

FDA Commissioner Announces Avastin Decision
US Food and Drug Administration (FDA) Commissioner Margaret A. Hamburg, M.D., said she is revoking the agency’s approval of the breast cancer indication for Avastin (bevacizumab) after concluding that the drug has not been shown to be safe and effective for that use. [Food and Drug Administration, United States] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW American Association for Cancer Research – Noncoding RNAs and Cancer
January 8-11, 2012
Miami Beach, United States

our events page to see a complete list of events in the mammary cell community.

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Research and Development Technologist, hPSC Media (STEMCELL Technologies)

Lab Technologist – Pluripotent Stem Cells (STEMCELL Technologies)

Scientific Marketing Communications Specialist (STEMCELL Technologies, Inc.)

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Business Analyst – Product Management (STEMSOFT Software)

Postdoctoral Training Fellow, Molecular Pathology Team (The Institute of Cancer Research)

Postdoctoral Fellow in Breast Cancer (Indiana University School of Medicine)
Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally:
United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us